TY - JOUR
T1 - P3.07-019 AMDAT Lung, An Ideal Lung Cancer MDT Dataset
T2 - Topic: Other – Geographical Differences
AU - Stone, Emily
AU - Rankin, Nicole
AU - Phillips, Jane
AU - Fong, Kwun
AU - Miller, Alistair
AU - Largey, Geraldine
AU - Zielinski, Robert
AU - Flynn, Peter
AU - Currow, David
AU - Shaw, Tim
PY - 2017/1
Y1 - 2017/1
N2 - Local treatment for pulmonary oligometastases (one to five lesions) using metastasectomy or stereotactic ablative radiotherapy (SABR) was investigated in a cohort that received multidisciplinary tumor board–based treatment decisions. The first choice of treatment was surgery; SABR was recommended in cases of adverse clinical factors. Propensity score–adjusted and unadjusted overall survival was the primary end point; local control and time to failure of a local-only treatment strategy were also analyzed. With a minimum follow-up time of 5.8 years, the 5-year overall survival rate was 41% for surgery (n = 68) and 45% for SABR (n = 42). Again not different for the two modalities, 40% of patients were free from failure of a local-only treatment strategy, and 20% were free from any progression at 5 years. The 5-year local control rate was 83% for SABR and 81% for surgery. Despite treatment selection clearly disadvantaging SABR against surgery, even unadjusted outcome was not better when pulmonary oligometastases were surgically removed rather than irradiated.
AB - Local treatment for pulmonary oligometastases (one to five lesions) using metastasectomy or stereotactic ablative radiotherapy (SABR) was investigated in a cohort that received multidisciplinary tumor board–based treatment decisions. The first choice of treatment was surgery; SABR was recommended in cases of adverse clinical factors. Propensity score–adjusted and unadjusted overall survival was the primary end point; local control and time to failure of a local-only treatment strategy were also analyzed. With a minimum follow-up time of 5.8 years, the 5-year overall survival rate was 41% for surgery (n = 68) and 45% for SABR (n = 42). Again not different for the two modalities, 40% of patients were free from failure of a local-only treatment strategy, and 20% were free from any progression at 5 years. The 5-year local control rate was 83% for SABR and 81% for surgery. Despite treatment selection clearly disadvantaging SABR against surgery, even unadjusted outcome was not better when pulmonary oligometastases were surgically removed rather than irradiated.
KW - Lung metastases
KW - Oligometastases
KW - Pulmonary metastasectomy
KW - Stereotactic ablative radiotherapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85021431655&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2016.11.2210
DO - 10.1016/j.jtho.2016.11.2210
M3 - Article
SN - 1556-0864
VL - 12
SP - S1442
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - Supplement 1
ER -